Zhou L, Chen Y, Li Y, Wu C, Xue C, Wang X
Front Oncol. 2024; 13:1323534.
PMID: 38234405
PMC: 10792117.
DOI: 10.3389/fonc.2023.1323534.
Ramos C, Oehler R
Cell Death Discov. 2024; 10(1):26.
PMID: 38218739
PMC: 10787834.
DOI: 10.1038/s41420-024-01809-7.
Tawfik N, Mohamed W, Mahmoud H, Alqarni M, Naguib I, Fahmy A
Antioxidants (Basel). 2022; 11(4).
PMID: 35453384
PMC: 9027254.
DOI: 10.3390/antiox11040699.
DSilva M, Na H, Cho J, Han H, Yoon Y, Lee H
Transl Cancer Res. 2022; 10(7):3345-3355.
PMID: 35116640
PMC: 8798651.
DOI: 10.21037/tcr-21-707.
Haak V, Huang S, Panigrahy D
Cancer Metastasis Rev. 2021; 40(3):791-801.
PMID: 34665387
PMC: 8524220.
DOI: 10.1007/s10555-021-09998-8.
Eicosanoid regulation of debris-stimulated metastasis.
Deng J, Yang H, Haak V, Yang J, Kipper F, Barksdale C
Proc Natl Acad Sci U S A. 2021; 118(41).
PMID: 34607951
PMC: 8521662.
DOI: 10.1073/pnas.2107771118.
Exploitation of Apoptotic Regulation in Cancer.
Ucker D, Levine J
Front Immunol. 2018; 9:241.
PMID: 29535707
PMC: 5835066.
DOI: 10.3389/fimmu.2018.00241.
Clinicopathologic Correlations of E-cadherin and Prrx-1 Expression Loss in Hepatocellular Carcinoma.
Yi K, Kim H, Chung Y, Ahn H, Sim J, Wi Y
J Pathol Transl Med. 2016; 50(5):327-36.
PMID: 27580127
PMC: 5042901.
DOI: 10.4132/jptm.2016.06.22.
Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis.
Luo Y, Ren F, Liu Y, Shi Z, Tan Z, Xiong H
Int J Clin Exp Med. 2015; 8(7):10235-47.
PMID: 26379815
PMC: 4565198.
Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.
Niu Z, Niu X, Wang M
World J Hepatol. 2015; 7(1):7-27.
PMID: 25624992
PMC: 4295195.
DOI: 10.4254/wjh.v7.i1.7.
Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression.
Wu Y, Jiang W, Wang Y, Wu J, Saiyin H, Qiao X
PLoS One. 2012; 7(8):e42976.
PMID: 22927944
PMC: 3424258.
DOI: 10.1371/journal.pone.0042976.
Assessment of the Proliferative Marker Ki-67 and p53 Protein Expression in HBV- and HCV-related Hepatocellular Carcinoma Cases in Egypt.
Mohamed W, Omar M, Khayri T, Fakhr I
Int J Health Sci (Qassim). 2011; 2(1):27-34.
PMID: 21475468
PMC: 3068722.
Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma.
Tatsuwaki H, Tanigawa T, Watanabe T, Machida H, Okazaki H, Yamagami H
Cancer Sci. 2009; 101(2):550-8.
PMID: 19917058
PMC: 11159708.
DOI: 10.1111/j.1349-7006.2009.01390.x.
Hepatic progenitor cells in human liver tumor development.
Libbrecht L
World J Gastroenterol. 2006; 12(39):6261-5.
PMID: 17072946
PMC: 4088131.
DOI: 10.3748/wjg.v12.i39.6261.
Construction and clinical significance of a predictive system for prognosis of hepatocellular carcinoma.
Cui J, Dong B, Liang P, Yu X, Yu D
World J Gastroenterol. 2005; 11(20):3027-33.
PMID: 15918184
PMC: 4305834.
DOI: 10.3748/wjg.v11.i20.3027.
Induction of apoptosis in mouse liver adenoma and carcinoma in vivo by transforming growth factor-beta1.
Chabicovsky M, Wastl U, Taper H, Grasl-Kraupp B, Schulte-Hermann R, Bursch W
J Cancer Res Clin Oncol. 2003; 129(9):536-42.
PMID: 12905009
DOI: 10.1007/s00432-003-0460-8.
The prognostic molecular markers in hepatocellular carcinoma.
Qin L, Tang Z
World J Gastroenterol. 2002; 8(3):385-92.
PMID: 12046056
PMC: 4656407.
DOI: 10.3748/wjg.v8.i3.385.
Hepatocellular carcinomas in native livers from patients treated with orthotopic liver transplantation: biologic and therapeutic implications.
Kirimlioglu H, Dvorchick I, Ruppert K, Finkelstein S, Marsh J, Iwatsuki S
Hepatology. 2001; 34(3):502-10.
PMID: 11526535
PMC: 2956439.
DOI: 10.1053/jhep.2001.26633.
Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma.
Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K
Br J Cancer. 2001; 84(10):1377-83.
PMID: 11355950
PMC: 2363640.
DOI: 10.1054/bjoc.2000.1580.